medmix Board of Directors nominate Rob ten Hoedt as proposed Chairman of the Board, for election at the AGM 2023

Ad hoc announcement pursuant to Art. 53 LR |

November 30, 2022

 

medmix Board of Directors nominate Rob ten Hoedt as proposed Chairman of the Board, for election at the AGM 2023

 

The Board of Directors has unanimously decided to nominate current Director Rob ten Hoedt as proposed Chairman of the Board of Directors, for election at the AGM 2023. Rob ten Hoedt is currently the Executive Vice President & President, Global Regions of Medtronic. Rob is also the Chairman of the Board of MedTech Europe, the Association representing the medical technology industry in Europe.

 

As previously announced, Greg Poux-Guillaume, who became Chief Executive Officer of AkzoNobel on November 01, 2022, will not stand for re-election as Chairman of the Board of medmix but will be proposed for re-election as a Director.

 

These changes to the Board of Directors are subject to approval at the 2023 Annual General Meeting.

 

Please visit www.medmix.swiss/company/leadership for more information on Rob ten Hoedt and Greg Poux-Guillaume.

 

Key dates in 2023

22 February 2023	Full year results 2022
28 April 2023	AGM 2023

 

 

About medmix

medmix is a global leader in high-precision delivery devices. We occupy leading positions in the healthcare, consumer and industrial end-markets. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 13 production sites worldwide together with our highly motivated and experienced team of 1’900 employees provide our customers with uncompromising quality, proximity and agility. medmix is currently headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX).

www.medmix.swiss

 

Inquiries:

Media Relations: IRF, Yasemin Diethelm

medmix@irf-reputation.ch 

 

 

This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.